Veracyte appoints Kevin Haas as chief development and technology officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Veracyte Names Kevin Haas as Chief Development and Technology Officer
March 16, 2026 4:15 PM EDTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the companys global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he... More
